1,366 results on '"Pantuck, Allan J."'
Search Results
102. Proteomic Identification of Interleukin-2 Therapy Response in Metastatic Renal Cell Cancer
103. The Chemokine Receptor CXCR3 is an Independent Prognostic Factor in Patients With Localized Clear Cell Renal Cell Carcinoma
104. MITOGEL: OPTIMIZING DRUG DELIVERY TO THE UPPER URINARY TRACT—A PRECLINICAL EVALUATION: MP77-08
105. INITIAL MULTICENTER EXPERIENCE UTILIZING AN ABSORBABLE RADIOPAQUE HYDROGEL FOR PATIENTS WITH INVASIVE BLADDER TUMORS: MP61-17
106. THE ROLE OF OBESITY IN THE INCIDENCE OF LYMPHATIC SPREAD, DISEASE-FREE AND OVERALL SURVIVAL: DATA FROM THE ARISER CLINICAL TRIAL: MP36-19
107. VALIDATION OF THE CAIX SCORE AS A PROGNOSTIC BIOMARKER FOR LYMPHATIC SPREAD AND CANCER-SPECIFIC SURVIVAL: MP36-12
108. EFFECTS OF DENDRITIC CELL-BASED AD-GM·CAIX VACCINE AS MONOTHERAPY OR IN COMBINATION WITH SUNITINIB IN AN IMMUNOCOMPETENT MOUSE MODEL OF METASTATIC RENAL CELL CARCINOMA: MP35-06
109. A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
110. Genomics and proteomics in renal cell carcinoma: Diagnosis, prognosis, and treatment selection
111. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma
112. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
113. Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase the Performance of Established Predictors of Renal Cell Carcinoma-Specific Mortality
114. Long-term outcomes of the surgical management of renal cell carcinoma
115. Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience
116. Morbidity and Clinical Outcome of Nephron-Sparing Surgery in Relation to Tumour Size and Indication
117. Ureteral tumor thrombus from renal cell carcinoma extending into bladder
118. A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
119. The Prevalence of Malignancy in Satellite Renal Lesions and its Surgical Implication During Nephron Sparing Surgery
120. Prognostic Factors for Renal Cell Carcinoma With Tumor Thrombus Extension
121. Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience
122. Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval
123. G250: A carbonic anhydrase IX monoclonal antibody
124. Reply by Authors
125. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
126. Etiology of Renal Cell Carcinoma: Incidence, Demographics, and Environmental Factors
127. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
128. Minimally invasive ablative approaches in the treatment of renal cell carcinoma
129. Immunotherapy of prostate cancer
130. Treatment of Localized Kidney Cancer
131. Dendritic cell-based immunotherapy of renal cell carcinoma
132. Molecular-based therapies for renal cell carcinoma
133. Prevention of Bladder Cancer: A Review
134. Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications
135. Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions
136. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma
137. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma
138. ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING: 2003
139. NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA: 2002
140. UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: 979
141. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival
142. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance
143. Use of Abiraterone for Prostate Cancer
144. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?
145. Differential expression of melanoma-associated antigen A3/6 and associated immune molecules prior to and post treatment with immune checkpoint inhibitors (ICI) in patients with mUC.
146. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma
147. Percent Microscopic Tumor Necrosis and Survival After Curative Surgery for Renal Cell Carcinoma
148. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy
149. Editorial Comment
150. Bladder Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.